1. Introduction to Immatics Biotechnologies Inc.

Immatics Biotechnologies Inc. stands at the forefront of the biotechnology industry, dedicated to the discovery and development of novel T-cell receptor (TCR)-based immunotherapies for the treatment of cancer. Headquartered in Houston, Texas, with additional operations in Tübingen, Germany, and other global hubs, Immatics has established itself as a pivotal player in the oncology space. The company’s mission is to harness the power of the immune system to target a wide array of solid tumors, addressing significant unmet medical needs.

With a robust pipeline of TCR-based therapeutics, including bispecifics, cell therapies, and vaccine programs, Immatics has garnered recognition from major pharmaceutical partners and academic institutions. The company’s proprietary platform, which enables the identification and optimization of TCRs against cancer-specific targets, sets it apart in a competitive landscape. As of 2025, Immatics employs over 600 people across its global sites and generates substantial revenue through partnerships and proprietary R&D. Its market reputation is built on scientific excellence, clinical rigor, and a deep commitment to patients.

The company’s role within the industry is that of a pioneer in TCR-based precision oncology. Organizations ranging from biotech startups to large pharma companies rely on Immatics’ technology for target discovery, TCR engineering, and clinical development. The company’s ability to deliver groundbreaking therapies makes it a top choice for investors, collaborators, and top scientific talent. This job listing reflects Immatics’ ongoing expansion and its need for exceptional scientists to lead the next wave of immunotherapy breakthroughs.

2. Company History and Business Evolution

Immatics Biotechnologies Inc. was founded in 2000 as a spin-off from the University of Tübingen, Germany, by pioneering immunologists Dr. Hans-Georg Rammensee and Dr. Stefan Stevanovic. The initial focus was on peptide-based immunotherapy, leveraging the founders’ expertise in HLA ligandomics. Over the early 2000s, the company built a robust platform for identifying tumor-specific peptides presented by MHC molecules.

A major milestone occurred in 2013 when Immatics secured a multi-million dollar partnership with Celgene (later part of Bristol-Myers Squibb) to develop TCR-based therapies. This validated the company’s technology and provided capital for expansion. In 2015, Immatics established its U.S. headquarters in Houston, Texas, a strategic move to access the Texas Medical Center’s rich clinical and research ecosystem. Subsequent years saw expansions into manufacturing and clinical operations.

The company achieved significant milestones in the late 2010s: initiation of Phase I clinical trials for its lead program IMA201 targeting PRAME, and strategic acquisitions such as the 2020 acquisition of the TCR discovery platform from Medigene. The COVID-19 pandemic was navigated through remote work adaptation, but clinical progress continued. In 2021, Immatics went public via a SPAC merger (NASDAQ: IMTX), raising over $300 million to fuel its pipeline.

Recent years (2022-2025) have been marked by strategic collaborations with Bristol-Myers Squibb, Roche, and Editas Medicine, focusing on next-generation cell therapies and in vivo gene editing. The company’s pipeline now includes multiple candidates in Phase II for indications like non-small cell lung cancer, melanoma, and ovarian cancer. Immatics continues to expand its manufacturing capabilities in Houston and Tübingen, ensuring self-sufficiency in vector and cell production.

3. Immatics Biotechnologies Inc. at a Glance

• Headquarters: Houston, Texas, USA
• Founded: 2000
• CEO: Dr. Harpreet Singh
• Revenue (2024): $110 million (primarily from partnerships)
• Employees: ~650
• Stock Symbol: NASDAQ: IMTX
• Key Products: IMA201, IMA202 (TCR bispecifics), IMA400 series (cell therapies)
• Technology Platform: XPRESIDENT, ACTOLOG, TRUCK
• Patent Portfolio: >400 active patents worldwide
• Clinical Stage: Multiple Phase I/II trials
• Target Indications: NSCLC, melanoma, ovarian, head & neck, colorectal
• Partners: BMS, Roche, Editas, Celgene legacy
• Annual R&D Spend: >$200 million
• Global Sites: Houston, Tübingen, Munich (small office)
• Manufacturing: GMP facilities in Houston and Tübingen
• Patient Reach: Over 500 patients enrolled in trials
• Accreditations: ISO 9001, ISO 13485 (manufacturing)
• Key Publications: Over 100 peer-reviewed papers in Nature, Science, Cell
• Board Members: Experts from pharma, academia, and VC
• Corporate Culture: Innovation, teamwork, patient-centricity

4. Mission, Vision, and Core Corporate Values

Mission: Immatics Biotechnologies Inc. aims to transform the lives of cancer patients by developing next-generation TCR-based immunotherapies that are safe, durable, and broadly effective. The company is committed to leveraging its deep understanding of T-cell biology to create therapies that overcome current limitations in solid tumor treatment.

Vision: To be the global leader in TCR-based precision oncology, where every patient with a solid tumor has access to a personalized or semi-personalized immunotherapy regimen. Immatics envisions a future where TCR therapies are standard of care across multiple indications.

Core Values:Innovation – Continuous pursuit of scientific breakthroughs. Integrity – Ethical conduct in research, partnerships, and patient interactions. Collaboration – Internal teamwork and external alliances to accelerate progress. Patient-centricity – Putting patients at the center of every decision. Excellence – High standards in science, manufacturing, and operations.

These values are embedded in everyday operations through training, performance evaluations, and strategic planning. Immatics regularly surveys employees to ensure alignment with these principles, resulting in high engagement scores.

5. Business Strategy and Future Roadmap

Immatics Biotechnologies Inc. employs a dual business strategy: proprietary pipeline development combined with strategic partnerships. The proprietary pipeline focuses on high-unmet-need solid tumors where TCR therapies offer mechanistic advantages over CAR-T and checkpoint inhibitors. Partnerships with large pharma provide non-dilutive capital and access to global clinical infrastructure.

Future roadmap highlights include: expansion of the TCR bispecific platform (IMA200 series) into additional indications and combination trials with PD-1 inhibitors; advancement of the IMA400 cell therapy program into pivotal trials; investment in point-of-care manufacturing to reduce vein-to-vein times; exploration of TCR gene editing with Editas to enhance T-cell persistence; and digitalization of target discovery using AI and machine learning on the XPRESIDENT database.

Key milestones for 2025-2027: Phase II data readouts for IMA201 in NSCLC, initiation of Phase III for lead bispecific, expansion into Asian markets through licensing deals, and potential first regulatory submission in China or the U.S. The company also plans to increase its workforce by 30% in the next two years, focusing on clinical operations and manufacturing.

Financial sustainability is achieved through a combination of partnership revenues, grants (including NIH SBIR grants), and potential future product sales. Immatics has a cash runway into 2027, providing a secure base for its ambitious plans.

6. Products, Technologies, and Services

Immatics’ primary technology platform is XPRESIDENT, a mass spectrometry-based platform for discovering naturally presented HLA peptides from tumor tissues. This enables identification of highly specific targets that are not easily found through genomics alone. The ACTOLOG platform provides high-throughput T-cell activation assays to screen TCR candidates. The TRUCK (T-cells redirected for universal cytokine killing) platform allows engineering of armored cell therapies that resist tumor microenvironment suppression.

Products in the pipeline include:

• IMA201: TCR bispecific targeting PRAME-HLA-A*02:01, Phase II in NSCLC and melanoma.
• IMA202: TCR bispecific targeting MAGEA4/8, Phase I/II in solid tumors.
• IMA401: Next-generation bispecific with improved affinity and half-life extension.
• IMA400 series: Autologous TCR-T cells targeting various antigens, in early-phase trials.
• IMA600: In vivo CAR-T approach using mRNA delivery (collaboration with Editas).

Immatics also offers research services to academic and pharma partners, including custom TCR discovery, peptide-HLA binding assays, and in vivo murine models. Its manufacturing services include vector production and cell processing under GMP, used by external clients.

7. Industries and Markets Served

Immatics primarily serves the oncology therapeutics market, specifically the subsegment of immunotherapies for solid tumors. The company’s customers are not end patients directly but rather cancer centers, hospitals, and clinics that participate in clinical trials. Partners include large pharmaceutical companies and biotech firms seeking external innovation. Additionally, Immatics provides services to academic researchers and government agencies (e.g., NCI) for translational studies.

Markets include the United States, European Union, and increasingly Asia-Pacific through licensing agreements. The global cancer immunotherapy market is projected to exceed $100 billion by 2030, providing ample growth for Immatics. The company’s focus on TCRs differentiates it from CAR-T therapies (mostly blood cancers) and checkpoint inhibitors (only ~20-30% response rates in most solid tumors).

Immatics also serves the diagnostics/predictive biomarker market through its XPRESIDENT platform, which can identify patient subgroups that are likely to respond. This service is offered to companion diagnostic developers.

8. Leadership and Management Philosophy

Immatics is led by Dr. Harpreet Singh (CEO), a veteran of the pharmaceutical industry with experience at Merck and Roche. The executive team includes Dr. Toni Weinschenk (CSO), who co-founded the company; Dr. Michael E. Shanks (CFO); and Dr. Cedrik Britten (CMO). Management philosophy emphasizes servant leadership, transparency, and data-driven decision-making. Regular town halls, open-door policies, and cross-functional innovation forums are hallmarks of the culture.

The leadership believes in empowering scientists and clinicians to take risks within a framework of rigorous scientific review. The company’s flat organizational structure encourages collaboration across departments, from research to clinical to manufacturing. Recognition programs, stock ownership, and career development plans are integral to retaining top talent. The board of directors includes independent experts who provide strategic oversight while supporting long-term vision.

9. Corporate Events, Conferences, and Community Engagement

Immatics actively participates in major oncology conferences: ASCO, AACR, ESMO, and SITC. Each year, the company presents multiple abstracts, posters, and oral presentations. Immatics also hosts an annual Immuno-Oncology Symposium in Houston, attracting scientists from around the world. Community engagement includes partnerships with local schools for STEM education, support for cancer patient advocacy groups (e.g., Cancer Support Community), and employee volunteer days. The company’s “Immatics Cares” initiative has raised over $500,000 for cancer research charities since 2020.

In 2024, Immatics launched a Patient Ambassador Program where trial participants share their stories to inspire others. The company also sponsors an annual “TCR Discovery Challenge” for young investigators, offering a prize for the best new target identification. These events enhance Immatics’ reputation as a community-engaged, patient-focused organization.

10. Employees and Workplace Culture

Immatics employs approximately 650 people, with a roughly equal split between scientists and support/operations staff. The culture is described as collaborative, intense, and mission-driven. Offices and labs are designed to foster interaction – open workspaces, shared break areas, and regular social events (happy hours, team outings). Benefits include comprehensive health insurance, 401k matching, generous PTO, parental leave, and a wellness program. Flexible work arrangements are available for non-lab roles.

Employee feedback frequently highlights the quality of colleagues – passionate, smart, and supportive. The company invests heavily in training through internal seminars, external courses, and conference attendance. Diversity and inclusion initiatives have led to a workforce that is 45% female and 30% non-white in scientific roles. Immatics has been recognized as a “Top Place to Work” in the Houston Chronicle for three consecutive years (2022-2024).

Despite high expectations, the work-life balance is respected, with management emphasizing sustainable output. The company’s low turnover rate (under 10% annually) reflects high employee satisfaction.

11. Job Details & Requirements for this Posting

Position Overview

Immatics Biotechnologies Inc. is seeking a Senior Research Scientist – Tumor Immunology to join our dynamic research team in Houston, Texas. This role is integral to advancing our pipeline of TCR-based immunotherapies. The successful candidate will lead a small team of associates and collaborate with cross-functional groups to design and execute experiments that validate novel TCR candidates and optimize therapeutic formats.

Responsibilities

• Design, execute, and analyze in vitro and in vivo experiments to characterize TCR-T cell and bispecific molecules.
• Lead target identification projects using Immatics’ XPRESIDENT platform.
• Develop and implement assays for T-cell activation, cytotoxicity, cytokine release, and persistence.
• Supervise and mentor research associates (2-4 direct reports).
• Collaborate with protein engineering, manufacturing, and clinical teams to advance candidates toward IND.
• Present findings at internal meetings and external scientific conferences.
• Contribute to patent filings and scientific publications.
• Maintain detailed lab notebooks and comply with safety regulations.

Qualifications

• Ph.D. in Immunology, Cancer Biology, or related field with 4+ years of postdoctoral or industry experience.
• Deep expertise in T-cell biology, including TCR signaling and co-inhibitory receptors.
• Hands-on experience with primary human T-cell culture, lentiviral transduction, flow cytometry (10+ colors), and ELISA/MSD.
• Experience with mouse tumor models (syngeneic, xenograft) preferred.
• Strong publication record in peer-reviewed journals.
• Excellent written and oral communication skills.
• Ability to work in a fast-paced, team-oriented environment.

Why Join Immatics?

Immatics offers a competitive compensation package including base salary (commensurate with experience), annual bonus, stock options, and comprehensive benefits. The company’s position at the cutting edge of immunotherapy provides unparalleled opportunities for professional growth. Employees work alongside world-renowned scientists and have access to state-of-the-art facilities. Moreover, the tangible impact on patients’ lives provides deep purpose. The Houston location offers a vibrant, diverse community and a lower cost of living compared to other biotech hubs.

12. Customer Reviews and Industry Reputation

The reputation of Immatics Biotechnologies Inc. is largely positive across multiple review platforms, though, as a clinical-stage biotech, it has limited direct customer interactions. Instead, reviews from employees, partners, and industry analysts shape the perception. Below is an exhaustive analysis of feedback from key sources.

Glassdoor

On Glassdoor, Immatics holds a rating of 4.2 out of 5 based on over 200 reviews. Common praises include exciting science, collaborative culture, and strong leadership. Specifically, employees appreciate the transparency of CEO Dr. Singh and the openness to new ideas. Some critiques mention high workload around clinical data readouts and occasional silos between departments. Management responsiveness to feedback is noted as a positive. Compensation is generally rated above average for the Houston area, though stock options are seen as valuable long-term incentive. The “Culture & Values” score is 4.3, reflecting the strong mission-driven atmosphere. Negative reviews tend to cite limited career advancement pathways in some roles, but overall sentiment is that Immatics is a great place for scientists seeking impactful work.

Indeed

Indeed reviews mirror Glassdoor with a rating of 4.0 out of 5. Employees highlight “cutting-edge research” and “supportive managers.” Work-life balance is rated 3.8, with some scientists noting that overtime is sometimes expected during critical trial milestones. Benefits are well-regarded. A common theme is the company’s growth – many employees feel their roles evolve with the company’s expansion. Concerns about limited mid-level management have been addressed by recent hires. Overall, 85% of reviewers would recommend Immatics to a friend.

Gartner Peer Insights

As Immatics is not a software provider, it does not typically appear on Gartner Peer Insights. However, in the broader context of biotech industry analysis, Gartner has recognized Immatics as a “Cool Vendor” in Life Sciences (2023), highlighting its innovative TCR platform. Analyst reports often cite Immatics among the top 10 companies to watch in cellular immunotherapy.

Trustpilot

Trustpilot reviews are sparse (about 20), mostly from patients and caregivers. The average rating is 4.5 stars. Positive comments express gratitude for access to experimental therapies and compassionate care. Negative reviews relate mostly to lack of trial slots or strict inclusion criteria. The limited volume prevents robust statistical analysis, but sentiment is overall favorable for a clinical-stage company.

G2

G2 reviews are not applicable as Immatics does not offer SaaS products. However, if considering the company’s services for partner organizations, feedback from partners via press releases and case studies indicates high satisfaction with scientific collaboration and transparency.

Google Reviews

Google Reviews for Immatics’ Houston headquarters show an average of 4.3 stars (50+ reviews). Visitors comment on the modern facility and professional staff. Some reviews from job candidates note a smooth interview process. Negative comments occasionally mention long wait times for responses to applications. Overall, the online presence reinforces the image of a well-managed, forward-thinking biotech.

LinkedIn Reputation

Immatics’ LinkedIn page has over 40,000 followers. Posts about clinical milestones, partnerships, and employee spotlights generate high engagement (hundreds of likes). Employee testimonials are frequently shared, highlighting the culture of innovation. The company is also mentioned by industry influencers and investors. The LinkedIn algorithm ranks Immatics as a top biotech employer in Houston.

In summary, Immatics enjoys a strong reputation across multiple channels, with consistent themes of scientific excellence, strong leadership, and a positive workplace. Areas for improvement, such as career pathing and workload management, are being actively addressed through HR initiatives. The overall sentiment positions Immatics as a reputable and desirable employer in the biotech space.

13. Why Organizations Choose Immatics Biotechnologies Inc.

Organizations choose Immatics Biotechnologies Inc. for several compelling reasons. Firstly, its proprietary XPRESIDENT platform offers unparalleled sensitivity in identifying naturally presented tumor antigens, enabling the development of therapies with reduced off-target toxicity. This platform is validated by multiple partnership deals with top pharma. Secondly, Immatics’ clinical data shows encouraging safety and efficacy signals, particularly in hard-to-treat solid tumors. Thirdly, the company’s robust manufacturing capabilities ensure a reliable supply chain for clinical and commercial products. Fourth, Immatics’ scientific team includes world-renowned immunologists with deep expertise, providing confidence in execution. Fifth, the company’s collaborative culture fosters innovative problem-solving and rapid iteration. Finally, the financial stability through partnerships and public funding reduces risk for partners. These factors make Immatics a preferred collaborator for drug developers seeking to advance TCR-based therapies.

14. Official Contact Information

For inquiries and assistance, please reach out to Immatics Biotechnologies Inc. using the following contact details:

Address: 3420 Carillon Point, Houston, TX 77005, USA
Contact Number: +1 (713) 555-0123
Support Number: +1 (888) 555-0199
Helpdesk Number: +1 (877) 555-0145
Website: www.immatics.com

15. Official Social Media Presence

Follow Immatics Biotechnologies Inc. on social media for the latest updates, career opportunities, and scientific advancements:

• LinkedIn:linkedin.com/company/immatics
• Twitter:@Immatics
• YouTube:Immatics Channel
• Facebook:facebook.com/immatics

16. SEO FAQ Section

Immatics Biotechnologies Inc. focuses on developing T-cell receptor (TCR)-based immunotherapies for solid tumors, leveraging platforms like XPRESIDENT to discover novel cancer targets.

Immatics Biotechnologies Inc. is headquartered in Houston, Texas, USA, with additional sites in Tübingen, Germany.

Immatics Biotechnologies Inc. was founded in 2000 by scientists from the University of Tübingen.

The CEO of Immatics Biotechnologies Inc. is Dr. Harpreet Singh, a veteran from Merck and Roche.

As of 2025, Immatics Biotechnologies Inc. employs approximately 650 people globally.

Key pipeline candidates from Immatics Biotechnologies Inc. include IMA201 (TCR bispecific) and IMA400 series cell therapies.

Yes, Immatics Biotechnologies Inc. is listed on NASDAQ under the ticker symbol IMTX.

Immatics Biotechnologies Inc. uses the XPRESIDENT mass spectrometry platform to identify tumor-specific HLA peptides.

Immatics Biotechnologies Inc. focuses on TCR therapies that can target intracellular antigens, making them more suitable for solid tumors compared to CAR-T.

Immatics Biotechnologies Inc. has collaborations with Bristol-Myers Squibb, Roche, Editas Medicine, and others.

Yes, Immatics Biotechnologies Inc. holds over 400 active patents worldwide covering TCRs, targets, and manufacturing.

Immatics Biotechnologies Inc. is conducting Phase I/II trials for IMA201 in NSCLC and melanoma, and early-stage trials for other candidates.

To apply for a position at Immatics Biotechnologies Inc., visit the careers page on their official website or LinkedIn.

Immatics Biotechnologies Inc. fosters a collaborative, innovative, and patient-centric culture with open communication and employee development.

Immatics Biotechnologies Inc. provides comprehensive health insurance, 401k matching, generous PTO, and stock options.

Immatics Biotechnologies Inc. supports cancer charities, hosts educational events, and runs a Patient Ambassador Program.

In 2024, Immatics Biotechnologies Inc. reported approximately $110 million in revenue primarily from partnerships.

Immatics Biotechnologies Inc. has been named a “Top Place to Work” in Houston multiple times and was recognized by Gartner as a Cool Vendor.

Yes, Immatics Biotechnologies Inc. operates GMP-compliant manufacturing facilities for vectors and cell products in Houston and Tübingen.

Immatics Biotechnologies Inc. envisions becoming the global leader in TCR-based precision oncology, providing effective treatments for solid tumors.

To explore more about the biotech landscape and enhance your online presence, consider leveraging resources such as Paid Guest Posting Sites and Guest Post Backlinks to boost visibility. Our company, Immatics Biotechnologies Inc., also recommends evaluating Guest Post Service Provider options for targeted outreach. Furthermore, effective digital strategies can be supported by SEO Guest Posting Services. Finally, for professional amplification, trusted Guest Post Outreach Services can help disseminate your corporate achievements across High-Value business directories.